SG11202001182QA - Macrocyclic mcl-1 inhibitors and methods of use - Google Patents
Macrocyclic mcl-1 inhibitors and methods of useInfo
- Publication number
- SG11202001182QA SG11202001182QA SG11202001182QA SG11202001182QA SG11202001182QA SG 11202001182Q A SG11202001182Q A SG 11202001182QA SG 11202001182Q A SG11202001182Q A SG 11202001182QA SG 11202001182Q A SG11202001182Q A SG 11202001182QA SG 11202001182Q A SG11202001182Q A SG 11202001182QA
- Authority
- SG
- Singapore
- Prior art keywords
- inhibitors
- methods
- mcl
- macrocyclic
- macrocyclic mcl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D495/16—Peri-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/18—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D495/18—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762545853P | 2017-08-15 | 2017-08-15 | |
| US201762555475P | 2017-09-07 | 2017-09-07 | |
| US201862692663P | 2018-06-30 | 2018-06-30 | |
| PCT/US2018/000180 WO2019035911A1 (en) | 2017-08-15 | 2018-08-15 | Macrocyclic mcl-1 inhibitors and methods of use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202001182QA true SG11202001182QA (en) | 2020-03-30 |
Family
ID=65362347
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10202106345VA SG10202106345VA (en) | 2017-08-15 | 2018-08-15 | Macrocyclic mcl-1 inhibitors and methods of use |
| SG11202001182QA SG11202001182QA (en) | 2017-08-15 | 2018-08-15 | Macrocyclic mcl-1 inhibitors and methods of use |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10202106345VA SG10202106345VA (en) | 2017-08-15 | 2018-08-15 | Macrocyclic mcl-1 inhibitors and methods of use |
Country Status (21)
| Country | Link |
|---|---|
| US (3) | US10676485B2 (en) |
| EP (2) | EP3988555A1 (en) |
| JP (1) | JP2020531433A (en) |
| KR (1) | KR20200041942A (en) |
| CN (1) | CN111818917A (en) |
| AU (1) | AU2018316620A1 (en) |
| BR (1) | BR112020003180A2 (en) |
| CA (1) | CA3073112A1 (en) |
| CL (2) | CL2020000363A1 (en) |
| CO (1) | CO2020002678A2 (en) |
| CR (1) | CR20200124A (en) |
| EC (1) | ECSP20018703A (en) |
| IL (1) | IL272681A (en) |
| MX (1) | MX2020001717A (en) |
| PH (1) | PH12020500327A1 (en) |
| RU (1) | RU2020110517A (en) |
| SG (2) | SG10202106345VA (en) |
| TW (1) | TW201920194A (en) |
| UA (1) | UA126586C2 (en) |
| UY (1) | UY37843A (en) |
| WO (1) | WO2019035911A1 (en) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3073108A1 (en) * | 2017-08-15 | 2019-02-21 | Abbvie Inc. | Macrocyclic mcl-1 inhibitors and methods of use |
| US10676485B2 (en) * | 2017-08-15 | 2020-06-09 | Abbvie Inc. | Macrocyclic MCL-1 inhibitors and methods of use |
| JP2020531457A (en) * | 2017-08-15 | 2020-11-05 | アッヴィ・インコーポレイテッド | Macrocyclic MCL-1 inhibitor and method of use |
| TWI790271B (en) | 2017-08-15 | 2023-01-21 | 美商阿吉歐斯製藥公司 | Pyruvate kinase activators for use in treating blood disorders |
| CA3074641A1 (en) | 2017-09-07 | 2019-03-14 | Augusta University Research Institute, Inc. | Specific akt3 activator and uses thereof |
| CN109467538A (en) | 2017-09-07 | 2019-03-15 | 和记黄埔医药（上海）有限公司 | The heteroaryl cyclics and application thereof that cycloolefin replaces |
| US20230081720A1 (en) | 2019-05-20 | 2023-03-16 | Novartis Ag | Mcl-1 inhibitor antibody-drug conjugates and methods of use |
| CN117136076A (en) | 2020-11-24 | 2023-11-28 | 诺华股份有限公司 | MCL-1 inhibitor antibody drug conjugates and methods of use |
| TW202315637A (en) | 2021-06-11 | 2023-04-16 | 美商基利科學股份有限公司 | Combination mcl-1 inhibitors with anti-cancer agents |
| JP2024521947A (en) | 2021-06-11 | 2024-06-04 | ギリアード サイエンシーズ， インコーポレイテッド | Combination of MCL-1 inhibitors with antibody drug conjugates |
| TW202408588A (en) | 2022-05-20 | 2024-03-01 | 瑞士商諾華公司 | Antibody-drug conjugates of antineoplastic compounds and methods of use thereof |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2276346B1 (en) | 2008-04-30 | 2016-11-23 | National Health Research Institutes | Fused bicyclic pyrimidine compounds as aurora kinase inhibitors |
| FR3015483B1 (en) * | 2013-12-23 | 2016-01-01 | Servier Lab | NOVEL THIENOPYRIMIDINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME |
| JO3474B1 (en) * | 2014-08-29 | 2020-07-05 | Amgen Inc | Tetrahydronaphthalene derivatives that inhibit mcl-1 protein |
| FR3037957B1 (en) | 2015-06-23 | 2019-01-25 | Les Laboratoires Servier | NOVEL HYDROXYESTER DERIVATIVES, PROCESS FOR PREPARING THEM AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME |
| FR3037959B1 (en) | 2015-06-23 | 2017-08-04 | Servier Lab | NOVEL BICYCLIC DERIVATIVES, PROCESS FOR PREPARING THEM AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME |
| FR3037958B1 (en) | 2015-06-23 | 2019-01-25 | Les Laboratoires Servier | NOVEL HYDROXY ACID DERIVATIVES, PROCESS FOR PREPARING THEM AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM |
| FR3037956B1 (en) | 2015-06-23 | 2017-08-04 | Servier Lab | NOVEL AMINO ACID DERIVATIVES, PROCESS FOR PREPARING THEM AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME |
| FR3046792B1 (en) | 2016-01-19 | 2018-02-02 | Les Laboratoires Servier | NOVEL AMMONIUM DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM |
| KR102388208B1 (en) | 2016-04-22 | 2022-04-18 | 아스트라제네카 아베 | Macrocyclic MCL1 Inhibitors to Treat Cancer |
| TWI759316B (en) | 2016-07-22 | 2022-04-01 | 法商施維雅藥廠 | Combination of a bcl-2 inhibitor and a mcl1 inhibitor, uses and pharmaceutical compositions thereof |
| AU2017350499B2 (en) | 2016-10-28 | 2023-08-10 | Les Laboratoires Servier | Liposomal formulation for use in the treatment of cancer |
| WO2018126898A1 (en) | 2017-01-05 | 2018-07-12 | 河南美泰宝生物制药有限公司 | Thienopyrimidine derivative, preparation method therefor, and application thereof in manufacturing of antitumor drugs |
| UY37560A (en) | 2017-01-06 | 2018-07-31 | Servier Lab | COMBINATION OF AN MCL-1 INHIBITOR AND A TAXAN COMPOUND, USES AND PHARMACEUTICAL COMPOSITIONS OF THIS |
| US10676485B2 (en) * | 2017-08-15 | 2020-06-09 | Abbvie Inc. | Macrocyclic MCL-1 inhibitors and methods of use |
| JP2020531457A (en) * | 2017-08-15 | 2020-11-05 | アッヴィ・インコーポレイテッド | Macrocyclic MCL-1 inhibitor and method of use |
| CA3073108A1 (en) * | 2017-08-15 | 2019-02-21 | Abbvie Inc. | Macrocyclic mcl-1 inhibitors and methods of use |
| CN107573360B (en) | 2017-10-27 | 2019-08-09 | 都创(上海)医药科技有限公司 | A kind of preparation method of multiple target point small molecule compound S63845 |
-
2018
- 2018-08-15 US US15/998,789 patent/US10676485B2/en active Active
- 2018-08-15 AU AU2018316620A patent/AU2018316620A1/en not_active Abandoned
- 2018-08-15 EP EP21197248.4A patent/EP3988555A1/en active Pending
- 2018-08-15 KR KR1020207007568A patent/KR20200041942A/en not_active Application Discontinuation
- 2018-08-15 EP EP18846737.7A patent/EP3652184A1/en not_active Withdrawn
- 2018-08-15 RU RU2020110517A patent/RU2020110517A/en unknown
- 2018-08-15 JP JP2020508463A patent/JP2020531433A/en active Pending
- 2018-08-15 SG SG10202106345VA patent/SG10202106345VA/en unknown
- 2018-08-15 CN CN201880066986.9A patent/CN111818917A/en active Pending
- 2018-08-15 MX MX2020001717A patent/MX2020001717A/en unknown
- 2018-08-15 WO PCT/US2018/000180 patent/WO2019035911A1/en unknown
- 2018-08-15 BR BR112020003180-1A patent/BR112020003180A2/en unknown
- 2018-08-15 CA CA3073112A patent/CA3073112A1/en active Pending
- 2018-08-15 SG SG11202001182QA patent/SG11202001182QA/en unknown
- 2018-08-15 UY UY0001037843A patent/UY37843A/en not_active Application Discontinuation
- 2018-08-15 CR CR20200124A patent/CR20200124A/en unknown
- 2018-08-15 TW TW107128523A patent/TW201920194A/en unknown
- 2018-08-15 UA UAA202001749A patent/UA126586C2/en unknown
-
2020
- 2020-02-12 CL CL2020000363A patent/CL2020000363A1/en unknown
- 2020-02-13 PH PH12020500327A patent/PH12020500327A1/en unknown
- 2020-02-14 IL IL272681A patent/IL272681A/en unknown
- 2020-03-10 CO CONC2020/0002678A patent/CO2020002678A2/en unknown
- 2020-03-13 EC ECSENADI202018703A patent/ECSP20018703A/en unknown
- 2020-05-11 US US16/872,279 patent/US20200325153A1/en not_active Abandoned
- 2020-11-12 CL CL2020002943A patent/CL2020002943A1/en unknown
-
2022
- 2022-02-03 US US17/649,906 patent/US20230183261A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP3988555A1 (en) | 2022-04-27 |
| CR20200124A (en) | 2020-09-28 |
| SG10202106345VA (en) | 2021-07-29 |
| JP2020531433A (en) | 2020-11-05 |
| BR112020003180A2 (en) | 2020-09-15 |
| EP3652184A4 (en) | 2020-05-20 |
| UA126586C2 (en) | 2022-11-02 |
| PH12020500327A1 (en) | 2020-10-12 |
| MX2020001717A (en) | 2020-10-08 |
| AU2018316620A1 (en) | 2020-03-12 |
| CN111818917A (en) | 2020-10-23 |
| UY37843A (en) | 2019-03-29 |
| CO2020002678A2 (en) | 2020-08-10 |
| US20190144465A1 (en) | 2019-05-16 |
| US20200325153A1 (en) | 2020-10-15 |
| RU2020110517A3 (en) | 2022-03-23 |
| EP3652184A1 (en) | 2020-05-20 |
| CL2020002943A1 (en) | 2021-03-12 |
| TW201920194A (en) | 2019-06-01 |
| US10676485B2 (en) | 2020-06-09 |
| CL2020000363A1 (en) | 2020-06-12 |
| ECSP20018703A (en) | 2020-04-22 |
| RU2020110517A (en) | 2021-09-16 |
| US20230183261A1 (en) | 2023-06-15 |
| KR20200041942A (en) | 2020-04-22 |
| IL272681A (en) | 2020-03-31 |
| WO2019035911A1 (en) | 2019-02-21 |
| CA3073112A1 (en) | 2019-02-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL272681A (en) | Macrocyclic mcl-1 inhibitors and methods of use | |
| HK1259232A1 (en) | Substituted inhibitors of menin-mll and methods of use | |
| EP3668504A4 (en) | Macrocyclic mcl-1 inhibitors and methods of use | |
| EP3700527A4 (en) | Papd5 inhibitors and methods of use thereof | |
| HK1249513A1 (en) | Fused-tricyclic inhibitors of kras and methods of use thereof | |
| HK1258821A1 (en) | Bridged bicyclic inhibitors of menin-mll and methods of use | |
| EP3684361A4 (en) | Substituted inhibitors of menin-mll and methods of use | |
| HK1248499A1 (en) | Expandable body device and method of use | |
| IL267291B (en) | Ectonucleotidase inhibitors and methods of use thereof | |
| EP3668502A4 (en) | Macrocyclic mcl-1 inhibitors and methods of use | |
| ZA201905677B (en) | Glycan-interacting compounds and methods of use | |
| EP3510040A4 (en) | Ectonucleotidase inhibitors and methods of use thereof | |
| EP3268369A4 (en) | Anti-alphavbeta1 integrin inhibitors and methods of use | |
| FI3548033T3 (en) | Compounds and their methods of use | |
| IL259801A (en) | Inhibitors of ezh2 and methods of use thereof | |
| RS64271B1 (en) | Inhibitors of trpc6 | |
| IL279475A (en) | Ectonucleotidase inhibitors and methods of use thereof | |
| IL274504A (en) | Acss2 inhibitors and methods of use thereof | |
| PT3621694T (en) | Lrrc33 inhibitors and use thereof | |
| IL267238A (en) | Heparanase inhibitors and use thereof | |
| IL283782A (en) | Anellosomes and methods of use | |
| PL3362450T3 (en) | N1- and n7-substituted sibiriline derivatives and their use as inhibitors of cellular necroptosis | |
| IL266344A (en) | Inhibitors of mtor-deptor interactions and methods of use thereof | |
| IL267243A (en) | Heparanase inhibitors and use thereof | |
| EP3576745A4 (en) | Agents that inhibit ngly1 and methods of use thereof |